TG Therapeutics, Inc. (BIT:1TGTX)

Italy flag Italy · Delayed Price · Currency is EUR
33.38
-0.32 (-0.95%)
At close: Jul 18, 2025
-0.95%
Market Cap4.64B
Revenue (ttm)357.48M
Net Income (ttm)36.22M
Shares Outn/a
EPS (ttm)0.22
PE Ratio128.17
Forward PE26.31
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close33.70
Day's Rangen/a
52-Week Range29.65 - 40.00
Betan/a
RSI51.35
Earnings DateAug 4, 2025

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco... [Read more]

Industry Pharmaceutical Preparations
Founded 1993
Employees 338
Stock Exchange Borsa Italiana
Ticker Symbol 1TGTX
Full Company Profile

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Financial numbers in USD Financial Statements

News

There is no news available yet.